SAN DIEGO, Aug. 6, 2013 (GLOBE NEWSWIRE) -- REVA Medical, Inc. (ASX:RVA) ("REVA" or the "Company") will hold a conference call to discuss the Company's financial results through June 30, 2013 and its business outlook. Robert Stockman, Chairman and CEO, will host the call.
The call is scheduled for 4:00 p.m. US PDT on Tuesday, August 13, 2013 (which is 9:00 a.m. AEST on Wednesday, 14 August 2013) and may be accessed within the United States and Canada by dialing 1-877-312-5413 five minutes prior to the scheduled start time. Callers in Australia may access the call by dialing (02) 8223 9876. If you are asked to provide an access code, please spell out the word "REVA" to the operator and you will be connected promptly.
If you reside outside of the United States, Canada, or Australia, or if you prefer to access the audiocast through our website, please visit "Events & Presentations" under the "Investors" section of our website at www.revamedical.com, and click on the "listen to webcast" link. A replay of the audiocast will be available on our website after the call.
Mr. Stockman is also scheduled to present at the Canaccord Genuity 33rd Annual Growth Conference at 2:00 p.m. US EDT on Wednesday, August 14, 2013. The conference is being held August 14th and 15th at the Intercontinental Hotel in Boston, Massachusetts. A copy of the presentation materials will be posted in the "Investors" section of REVA's website at www.revamedical.com shortly before the presentation.
REVA is a development stage medical device company incorporated in Delaware, USA, that is focused on the development and eventual commercialization of its proprietary bioresorbable stent products. The ReZolve® product family, which is in a clinical study phase, combines REVA's proprietary stent design with a proprietary polymer that is metabolized and cleared from the body. REVA's anticipated commercial product, the ReZolve2 scaffold, is designed to offer full x-ray visibility, clinically relevant sizing, and a controlled and safe resorption rate. In addition, by early encapsulation of the stent in the artery tissue coupled with the loss of scaffold structure over time, the ReZolve2 scaffold may reduce the incidence of late forming blood clots or otherwise reduce long-term disease progression, potential benefits of bioresorbable scaffolds that have yet to be proven. REVA will require clinical results and regulatory approval before it can begin selling the ReZolve2 scaffold.
CONTACT: United States Investor and Media Enquiries: Cheryl Liberatore Director, Investor Relations and Marketing REVA Medical, Inc. +1 858 966-3045 Australia Investor Enquiries: Kim Jacobs Inteq Limited +61 2 9229 2700 Media Enquiries: Haley Price or Rebecca Wilson Buchan Consulting +61 3 9866 4722
Source:REVA Medical, Inc.